scholarly journals Activity of cancer procoagulant (CP) in serum of patients with cancer of lung, breast, oesophagus and colorectum.

1997 ◽  
Vol 44 (1) ◽  
pp. 109-112 ◽  
Author(s):  
M Rucińska ◽  
M Furman ◽  
Z Skrzydlewski ◽  
E Zaremba
Keyword(s):  
Blood Serum ◽  
Cancer Patients ◽  
Malignant Tumor ◽  
Clinical Stage ◽  
Healthy People ◽  
Colorectal Cancers ◽  
Patients With Cancer ◽  
Healthy Control ◽  
Cancer Procoagulant ◽  
Radical Removal

Activity of cancer procoagulant (CP) was studied in blood serum of 90 patients with cancer of lung, breast, oesophagus and colorectum, and of 15 healthy people. The activity of CP was determined by the coagulation method. Sera of patients with cancer showed higher mean activity of CP than sera of healthy control. Of the 90 cancer patients 78 were identified correctly by this test as having cancer (sensitivity 85%). In the case of lung and colorectal cancers the higher CP activity was observed the more advanced was the clinical stage of cancer, and the test was positive in 100%. After radical removal of malignant tumor of lung, decreased CP activity was found.

Paraneoplastic Syndromes in Patients with Cancer of the Larynx and Hypopharynx

2007 ◽  
Vol 116 (7) ◽  
pp. 502-513 ◽  
Author(s):  
Alfio Ferlito ◽  
Alessandra Rinaldo
Keyword(s):  
Cancer Patients ◽  
Malignant Tumor ◽  
World Literature ◽  
Paraneoplastic Syndromes ◽  
Malignant Neoplasms ◽  
Patients With Cancer ◽  
The World ◽  
Symptoms And Signs

Paraneoplastic syndromes may be the first sign of a malignancy. They are systemic, nonmetastatic manifestations associated with a variety of malignant neoplasms and occurring in a minority of cancer patients. These associations of symptoms and signs are not directly related to the site or local manifestations of a malignant tumor or its metastases, but their recognition may facilitate the detection of malignancies or recurrences. Paraneoplastic syndromes are categorized into 6 types: Dermatologic or cutaneous, endocrine, hematologic, neurologic, osteoarticular or rheumatologic, and ocular. Different oncotypes have rarely been associated with paraneoplastic syndromes in patients with cancer of the larynx and hypopharynx. The world literature has been reviewed.

scholarly journals Thrombocytosis as a predictor of thromboembolic complications in patients with malignant diseases

2017 ◽  
Vol 5 (6) ◽  
pp. 2506
Author(s):  
Siniša Maksimović ◽  
Siniša Maksimović ◽  
Aleksandar Jakovljević ◽  
Darko Jović ◽  
Ljiljana Latinović ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Anticoagulant Therapy ◽  
Clinical Stage ◽  
Massive Pulmonary Embolism ◽  
Therapeutic Modality ◽  
Thromboembolic Prophylaxis ◽  
Patients With Cancer ◽  
The Moment ◽  
Banja Luka ◽  
The University

Background: To prove the frequency of thrombocytosis in patients with cancer, and the importance of anticoagulant therapy. Thrombocytosis represents an elevated platelet count of more than 350,000/mm3 which is one of the risk factors for venous thromboembolism.Methods: This study has analyzed 146 patients who were hospitalized at the Oncology Clinic of the University Clinical Centre, Banja Luka and the Day Oncology Hospital “S.tetik”, Banja Luka in the period between 2009 and 2014. These were patients with breast tumor, gastrointestinal or gynecological malignancies. Thrombocytosis was detected in 38 patients in the moment of diagnosing. All examinees were analyzed by sex, age, primary site of tumor, presence of comorbidity, relevant laboratory analyses, clinical stage of the disease (metastatic or localized disease).Results: In the observed sample of 146 patients, thrombocytosis was detected in 38 patients in the moment of diagnosing the disease (26%). Through the follow-up, DVT (deep venous thrombosis) was found in 13 patients (34.2%) and anticoagulant therapy was administered. Out of patients who were not on anticoagulant therapy because they had no thrombotic manifestations (25 patients, 65.8%), 2 ended up experiencing the development of a clinical presentation of massive pulmonary embolism with fatal outcome.Conclusions: The occurrence of thromboembolism significantly increases morbidity and mortality, as well as the total cost of treating cancer patients. Regardless of the fact that cancer patients are at a high risk of thromboembolic events, thromboembolic prophylaxis has not been adopted as a standard therapeutic modality because of potential bleeding.

Determination of Serum Angiopioetin-2 levels in Breast cancer patients at Damascus University Hospitals

2021 ◽  
pp. 4856-4858
Author(s):  
Majd Haidar ◽  
Jumana Al Saleh
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Clinical Stage ◽  
Tumor Grade ◽  
Serum Levels ◽  
Breast Cancer Patients ◽  
University Hospitals ◽  
Healthy Control ◽  
Elisa Technique ◽  
Angiopoietin 2

Background: Breast cancer has increased universally. Angiogenesis is an essential step for cancer growth, progression and metastasis. Recent studies have focused on Angiopoietin-2 as a promising biomarker in prospecting the prognosis of the cancer. Objective: Determine the relation between serum concentrations of Angiopoietin-2 and clinicopathological data in breast cancer patients. Methodology: This study is prospective, cohort type. It includes 30 women with breast cancer, who met the study criteria. The serum Ang-2 value was calibrated using ELISA technique. The data was processed using SPSS program. Results: Ang-2 serum levels were statistically significant associated with ER status (P = 0.036). However, no signifi¬cant correlation was observed between serum Ang-2 level and the other clinicopathologic param¬eters tested, including Histological type (P = 0.417), Clinical grade G (P = 0.91), Clinical stage T (P = 0.913), Clinical stage N (P = 0.086), PR status (P = 0.467), and HER-2 status (P = 0.791). Serum levels of Ang-2 for breast cancer patients was significantly higher than healthy control (20411.33± 6283.19 vs 1731.70± 368.35 pg/ml, P< 0.000). our data indicates that serum levels of Ang-2 has no correlation between the tumor grade and stage in breast cancer patients.

scholarly journals Predictive Values of the Selected Inflammatory Index in the Progression of Colon Cancer Patients

2021 ◽  
Author(s):  
Li Huang ◽  
Zuojian Hu ◽  
Ruixian Luo ◽  
Hailan Li ◽  
Ziji Yang ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cancer Patients ◽  
Clinical Stage ◽  
Area Under The Curve ◽  
Diagnostic Efficacy ◽  
Ample Evidence ◽  
Predictive Values ◽  
Inflammatory Index ◽  
Healthy Control ◽  
Colon Diseases

Abstract Background: Ample evidence has revealed that the lymphocyte-to-monocyte ratio (LMR), albumin-to-globulin ratio (AGR) and mean platelet volume (MPV) are cancer-related inflammatory markers. The present study aimed to assess a better diagnostic marker for the progression of colon cancer. Methods: This retrospective study enrolled 251 patients with colon cancer, 171 patients with benign colon diseases, and 187 healthy control subjects from January 2012 to September 2020. The receiver operating characteristic (ROC) curve and area under the curve (AUC) were used to determine the diagnostic values of the selected inflammatory index.Results: The levels of LMR, AGR and MPV were decreased in the colon cancer group compared with the healthy control and benign colon disease groups. The LMR, AGR and MPV were all correlated with tumor size. Moreover, LMR and AGR was associated with lymph node metastasis and clinical stage, AGR was related to distant metastasis. Both the LMR (p = 0.030) and AGR (p = 0.005) were negatively correlated with the concentration of carcinoembryonic antigen (CEA). The AUC value of MPV combined with CEA had a good diagnostic ability for distinguishing controls from colon cancer cases (AUC = 0.950) and patients with benign colon diseases (AUC = 0.886). Meanwhile, the combination of LMR or AGR with CEA could enhance the diagnostic efficacy (AUC; 0.746 for LMR + CEA, 0.737 for AGR + CEA) of detecting colon cancer from benign colon diseases. Conclusions: CEA combined with the selected inflammatory index may be used as better blood-based biomarkers in the progression of colon cancer patients.

scholarly journals Unfavorable clinical implications of peripheral blood CD44+ and CD54+ lymphocytes in patients with lung cancer undergoing chemotherapy

2017 ◽  
Vol 33 (2) ◽  
pp. 208-214 ◽  
Author(s):  
Zhuanbo Luo ◽  
Yun Wang ◽  
Yanru Lou ◽  
Chao Cao ◽  
Richard Hubbard ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Peripheral Blood ◽  
Lymphocyte Subsets ◽  
Clinical Stage ◽  
Unmet Need ◽  
Control Group ◽  
Lung Cancer Patients ◽  
Healthy Control

Background: There is an unmet need for identification of additional prognostic markers for lung cancer. The aim of this study was to identify novel clinical and immunological predictors of prognosis in lung cancer patients. Methods: Lymphocyte subsets CD3+, CD4+, CD8+, CD4+/8+, CD25+, CD69+, CD44+ and CD54+ were quantified in peripheral blood using flow cytometry, for 203 newly diagnosed lung cancer patients and 120 healthy controls. Results: The levels of CD3+, CD4+, CD8+, CD4+/CD8+ and CD69+ lymphocytes were significantly lower in patients with lung cancer compared with the healthy control group, while CD54+ and CD44+ lymphocytes were significantly higher. In stage III/IV patients with lymph node metastasis or distant metastasis, the levels of CD44+ and CD54+ lymphocytes were significantly increased compared with patients with stage I/II disease (p<0.05). The levels of CD44+ and CD54+ lymphocytes markedly reduced after chemotherapy, and follow-up analysis indicated that patients found without increase of CD44+ and CD54+ lymphocytes after chemotherapy had survival advantages. Independent predictors of survival in lung cancer patients included clinical stage (hazard ratio [HR] = 2.791; 95% confidence interval [95% CI], 1.42-3.54, p<0.001), CD44+ lymphocytes (HR = 1.282; 95% CI, 1.02-1.49, p = 0.002) and CD54+ lymphocytes (HR = 1.475; 95% CI, 1.22-1.73, p = 0.003). Elevated levels of CD44+ and CD54+ lymphocytes correlated with poor prognosis in lung cancer patients. Conclusions: Peripheral blood lymphocyte subsets in patients with lung cancer are different from those in healthy people, and circulating CD44+ and CD54+ lymphocytes seem to be a promising criterion to predict survival in lung cancer patients undergoing chemotherapy.

scholarly journals Comparison of the Childhood Trauma, Mindfulness Attention Awareness and Integrative Self Knowledge in Cancer Patients and General Population

2021 ◽  
Vol 27 (1) ◽  
pp. 32-47
Author(s):  
Mohammad Saeed Khanjani ◽  
◽  
Shadan Mosavat ◽  
Bahman Bbahmani ◽  
Enayatollah Bakhshi ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Childhood Trauma ◽  
Healthy People ◽  
Childhood Trauma Questionnaire ◽  
Patients With Cancer ◽  
Treatment Processes ◽  
Significant Difference ◽  
Self Knowledge ◽  
Convenience Sampling

Objectives: This study aims to compare childhood trauma, integrative self-knowledge and mindfulness in patients with cancer and healthy people. Methods: This descriptive-analytical study was conducted on 139 patients with cancer and 139 healthy people referred to Firoozgar Hospital and SAMAR Charity House who were selected by a convenience sampling method. They were asked to complete Integrative Self-Knowledge (ISK) Questionnaire, Childhood Trauma Questionnaire (CTQ) and Mindfulness Attention Awareness Scale (MAAS). Data were analyzed using descriptive and inferential statistic methods including MANOVA. Results: There was a significant difference between patients and controls in terms of ISK (P<0.001), mindfulness (P<0.001) and childhood trauma (P<0.001). Conclusion: Cancer patients have lower ISK and mindfulness but higher childhood trauma compared to healthy people. Attention should be paid to the role of these factors in prevention and treatment processes.

Evaluation of the Concentration of Ubiquitin C Protein (UBC) in Patients of Lung Cancer and Comparing with Healthy Subjects

2020 ◽  
Vol 38 (2B) ◽  
pp. 61-65
Author(s):  
Abbas A. Mohammed ◽  
Saleen S. Abdulhadi
Keyword(s):  
Lung Cancer ◽  
Blood Serum ◽  
Cancer Patients ◽  
Normal Subjects ◽  
P Value ◽  
Cellular Functions ◽  
C Protein ◽  
Lung Cancer Patients ◽  
Healthy Control ◽  
The Mean

Ubiquitin protein has a conserved amino acid sequence, found in all eukaryotes and it is important in many of cellular functions .The increase or decrease in the ubiquitin level lead to causing many diseases including cancer .The aim of this study is to measure the concentration of ubiquitin c protein in blood serum of lung cancer patients and healthy control subjects by using ELISA technique. The Mean ± SD for ubiquitin c protein was (7.51 ± 5.76) in   blood serum of the normal healthy subject and   Std. Error mean was (1.82). While the Mean ± SD was (10.99 ± 4.56  ) for ubiquitin c protein in serum of  lung cancer patients and Std. Error mean  was  (1.44) .The results showed no statistically  significance the P value ( 0.15)  between  the  protein concentration in the serum of patients with lung cancer compared to the serum concentration of healthy normal  subjects.                                                                                                                                    

Treatment and secondary prevention of venous thromboembolism in cancer patients

2012 ◽  
Vol 03 (03) ◽  
pp. 121-125
Author(s):  
I. Pabinger ◽  
C. Ay
Keyword(s):  
Clinical Trials ◽  
Venous Thromboembolism ◽  
Cancer Patients ◽  
Oral Anticoagulants ◽  
Factor Xa ◽  
New Oral Anticoagulants ◽  
Phase Iii ◽  
Patients With Cancer ◽  
Potential Use

SummaryCancer is a major and independent risk factor of venous thromboembolism (VTE). In clinical practice, a high number of VTE events occurs in patients with cancer, and treatment of cancerassociated VTE differs in several aspects from treatment of VTE in the general population. However, treatment in cancer patients remains a major challenge, as the risk of recurrence of VTE as well as the risk of major bleeding during anticoagulation is substantially higher in patients with cancer than in those without cancer. In several clinical trials, different anticoagulants and regimens have been investigated for treatment of acute VTE and secondary prophylaxis in cancer patients to prevent recurrence. Based on the results of these trials, anticoagulant therapy with low-molecular-weight heparins (LMWH) has become the treatment of choice in cancer patients with acute VTE in the initial period and for extended and long-term anticoagulation for 3-6 months. New oral anticoagulants directly inhibiting thrombin or factor Xa, have been developed in the past decade and studied in large phase III clinical trials. Results from currently completed trials are promising and indicate their potential use for treatment of VTE. However, the role of the new oral thrombin and factor Xa inhibitors for VTE treatment in cancer patients still has to be clarified in further studies specifically focusing on cancer-associated VTE. This brief review will summarize the current strategies of initial and long-term VTE treatment in patients with cancer and discuss the potential use of the new oral anticoagulants.

Thrombosis in Cancer Patients Treated with Hematopoietic Growth Factors - A Meta-Analysis

1996 ◽  
Vol 75 (02) ◽  
pp. 368-371 ◽  
Author(s):  
T Barbul ◽  
G Finazzi ◽  
A Grassi ◽  
R Marchioli
Keyword(s):  
Cancer Patients ◽  
Case Reports ◽  
Meta Analysis ◽  
Case Series ◽  
Hematopoietic Growth Factors ◽  
Patients With Cancer ◽  
Cytotoxic Treatment ◽  
Pertinent Data ◽  
Thrombotic Complications ◽  
Vascular Occlusions

SummaryHematopoietic colony-stimulating factors (CSFs) are largely used in patients with cancer undergoing cytotoxic treatment to accelerate neutrophil recovery and decrease the incidence of febrile neutropenia. Clinical practice guidelines for their use have been recently established (1), taking into account clinical benefit, but also cost and toxicity. Vascular occlusions have been recently reported among the severe reactions associated with the use of CSFs, in anedoctal case reports (2, 3), consecutive case series (4) and randomized clinical trial (5, 6). However, the role of CSFs in the pathogenesis of thrombotic complications is difficult to ascertain, because pertinent data are scanty and widely distributed over a number of heterogenous investigations. We report here a systematic review of relevant articles, with the aims to estimate the prevalence of thrombosis associated with the use of CSFs and to assess if this rate is significantly higher than that observed in cancer patients not receiving CSFs.

Sign in / Sign up

Export Citation Format

Share Document